false
0001390478
0001390478
2026-03-11
2026-03-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): March 11, 2026
SELLAS
Life Sciences Group, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-33958 |
|
20-8099512 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
| |
|
|
|
|
| |
|
7 Times Square, Suite 2503
New York, NY 10036 |
|
|
| |
|
(Address of Principal Executive
Offices) (Zip Code) |
|
|
| |
|
|
|
|
| Registrant’s
telephone number, including area code: (646) 200-5278 |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
symbol(s) |
Name of each exchange
on which
registered |
| Common Stock, $0.0001 par value per share |
SLS |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
As previously reported on January 8, 2026, SELLAS
Life Sciences Group, Inc. (the “Company”) received approximately $26.5 million in proceeds as of such date from the exercise
of common stock warrants subsequent to December 31, 2025. Since January 8, 2026, the Company received approximately $16.1 million in proceeds
from the exercise of additional common stock warrants for a total of approximately $42.6 million in proceeds subsequent to December 31,
2025.
As of March 11, 2026, the Company had 179,536,724
shares of common stock outstanding.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number |
|
Description |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
SELLAS Life Sciences Group, Inc. |
| |
|
|
|
| Date: |
March 11, 2026 |
By: |
/s/ John T. Burns |
| |
|
|
Name: |
John T. Burns |
| |
|
|
Title: |
Senior Vice President, Chief Financial Officer |
